Background {#Sec1}
==========

Breast cancer is one of the most common malignancies in women, worldwide. Over the last 25 years, mortality has decreased by 36% leading to an increased number of breast cancer survivors \[[@CR1]\]. This considerable decline is likely attributable to advances in mammographic screening and improved surgical, radiation, and adjuvant therapies \[[@CR2]\]. However, cancer and cancer-directed treatment can incur serious long-term negative health effects. Thus, it is critical to monitor the potential impact of such late effects on breast cancer prognosis.

Hypothyroidism is a common hormone deficiency, characterised by insufficient production of triiodothyronine and thyroxine \[[@CR3]\]. The diagnosis of hypothyroidism is confirmed with blood tests measuring thyroid-stimulating hormone and thyroxine levels. Hypothyroidism requires substitution therapy. Despite adequate biochemical control, symptoms like fatigue or disturbed concentration do not always resolve. Hypothyroidism is diagnosed in about 3% of the population, more frequently in women, and risk increases with age; thus, some breast cancer patients develop hypothyroidism long before their breast cancer is diagnosed \[[@CR4]\].

Hypothyroidism is a well-documented late effect after radiation therapy in head and neck cancer \[[@CR5]\]. Consequently, a link between breast cancer treatment and subsequent risk of hypothyroidism has been discussed, initially by case reports published on breast cancer patients who developed hypothyroidism years after treatment \[[@CR6]--[@CR10]\]. Later, observational studies from Europe and the USA suggested that breast cancer patients may have a higher risk of hypothyroidism during follow-up \[[@CR11]--[@CR13]\]. Furthermore, several studies have linked types of cancer-directed treatments with hypothyroidism \[[@CR14]--[@CR18]\] and radiotherapy, particularly among those receiving radiotherapy to the supraclavicular region \[[@CR12]--[@CR14], [@CR19]\]. However, the scientific literature on the association of hypothyroidism with breast cancer prognosis is sparse. Laboratory-based animal models have shown that induced hypothyroidism without the use of substitution therapy may correlate with smaller, less-invasive tumours \[[@CR20]--[@CR22]\]. Thus, breast cancer patients with hypothyroidism may have a lower risk of breast cancer recurrence.

The aim of this study was first to investigate the association between hypothyroidism prevalent at breast cancer diagnosis, or incident during follow-up, and the subsequent risk of breast cancer recurrence in a large population-based cohort of breast cancer patients. Second, we investigated the association between hypothyroidism and all-cause mortality.

Methods {#Sec2}
=======

This study was approved by the Danish Data Protection Agency (Aarhus University, journal number 2016-051-000001, running number 437), the Danish Medicines Agency, and the Danish Breast Cancer Group (DBCG). According to Danish Law, ethical approval is not necessary because the study uses routinely collected registry data.

In Denmark, a unique civil personal registry number is assigned to all citizens at birth or immigration, enabling accurate and unambiguous individual-level record linkage across all public registries, medical as well as non-medical \[[@CR23]\]. Due to tax-funded healthcare, all 5.6 million citizens have free access to public hospitals, which covers more than 95% of hospitalisations including all emergencies.

Source population {#Sec3}
-----------------

We used the DBCG clinical database to ascertain information on all women 35 years or older with incident stage I-III, operable breast cancer on protocol treatment and diagnosed between January 1, 1996, and December 31, 2009 \[[@CR24]\]. The DBCG was established in 1977 to optimise diagnostic and therapeutic procedures across the country and to improve breast cancer prognosis \[[@CR25]\]. All patients with invasive breast cancer in Denmark are included prospectively, and registration completeness has increased over the years to reach \~ 95% for the last decade \[[@CR26], [@CR27]\]. The treating physicians are responsible for entering pre-specified data on patient, tumour, and treatment characteristics. We excluded women with prevalent hyperthyroidism at the time of the breast cancer diagnosis from the analyses.

Thyroid disease {#Sec4}
---------------

We defined hypothyroidism as a diagnostic code of hypothyroidism or the redemption of at least two prescriptions of levothyroxine. Information on diagnostic codes (International Classification of Diseases (ICD) 8: 244.00-244.03, 244.08, and 244.09, and ICD-10: E03.2-E03.9, and E89.0) was obtained from the Danish National Registry of Patients (DNRP) covering information on all discharge diagnoses for inpatient hospital contacts since 1977 and outpatient and emergency room hospital contacts since 1995 \[[@CR28]\]. We used the Danish National Prescription Registry (DNPR) to identify patients redeeming at least two prescriptions (Anatomical Therapeutic Classification (ATC) code: H03A) and to include patients treated for hypothyroidism but not necessarily recorded in the DNRP \[[@CR29]\].

To exclude women with hyperthyroidism from the study population, we identified diagnoses of hyperthyroidism in the DNRP by ICD-8: 242.01-242.29 and ICD-10: E05-E05.9 and E05.0B, or in the DNPR by redemption of at least two anti-thyroxine prescriptions (ATC codes: H03BB01, H03BB02, and H03BA02) during follow-up.

Outcomes {#Sec5}
--------

We used the DBCG definition of breast cancer recurrence as any local, regional, or distant recurrence or contralateral breast cancer \[[@CR25], [@CR26]\]. Regional recurrence includes recurrence in the same site as the first primary breast cancer in the axilla, supraclavicular, or parasternal lymph node region. All other recurrences are regarded as distant. When a new tumour is detected, a biopsy is taken for pathological assessment. The decision whether the new tumour is a recurrence of a previous cancer or a new primary tumour is based on this assessment in accordance with the clinical guidelines. Due to systematic follow-up, all cases of recurrence are reported in the DBCG including the date and anatomical site of recurrence. The systematic follow-up for patients with operable disease includes a clinical evaluation, biannually for the first 5 years and annually up to 10 years after diagnosis.

All-cause mortality included death from any cause in any setting. We obtained data on mortality from the Danish Civil Registration System, which has registered information on vital and migration status on all Danish inhabitants since 1968 \[[@CR23]\].

Covariates {#Sec6}
----------

From the DBCG, we retrieved clinical and treatment characteristics: menopausal status at diagnosis (pre/post), histological grade (a composite score including tubule formation, mitoses, and nuclear pleomorphy) (low, moderate, and high), lymph node status (N0, N1--3, N4+), tumour oestrogen receptor (ER) status (positive ≥ 10%/negative 0--9%), HER-2 status (classified according to immunohistochemistry (Hercept test) and by fluorescent in situ hybridisation (FISH) and available from 2007) (positive HER-2 score = 3 and FISH ≤ 2.00, negative HER-2 score ≤ 2 and FISH ≤ 2.00), and chemo-, radio-, and endocrine therapy (ET) (yes, no) (intention-to-treat information). We summarised the type of primary surgery and radiotherapy into a joint variable (mastectomy with radiotherapy, mastectomy without radiotherapy, lumpectomy) and ER and ET as a joint variable (ER+/ET+, ER+/ET−, ER−/ET+, and ER−/ET−).

We ascertained information on comorbidities diagnosed up to 10 years before primary breast cancer diagnosis from the DNRP. A modified comorbidity score was calculated for each patient according to the Charlson Comorbidity Index excluding cancer in the index score \[[@CR30]\]. Based on the score, three categories were computed (no comorbidity, low (score of 1 or 2), and high (score ≥ 3)).

Statistical analyses {#Sec7}
--------------------

We used a prevalent and an incident model for hypothyroidism as illustrated in Fig. [1](#Fig1){ref-type="fig"}. In the prevalent model, hypothyroidism was included as a baseline exposure. Women with a clinical diagnosis of hypothyroidism and/or redeemed prescriptions for thyroxine before or at the time of the breast cancer diagnosis were considered to have prevalent hypothyroidism. For incident hypothyroidism, exposed person-time started at the date of hypothyroidism or once a patient had redeemed at least two thyroxine prescriptions with prescriptions treated as a time-varying exposure lagged by 1 year (please see Additional file [1](#MOESM1){ref-type="media"}) \[[@CR31]\].Fig. 1Flowchart of including women for the study of breast cancer recurrence

Person-time at risk of recurrence was computed from the date of primary breast cancer surgery (index date) and continued to the date of breast cancer recurrence, death, emigration, hyperthyroidism, 10 years, or the first of June 2015 whichever came first. For all-cause mortality, person-time at risk was calculated from the index date and continued to the date of death, emigration, hyperthyroidism, 10 years, or the first of June 2015 whichever came first.

Within categories of patient, clinical, and treatment characteristics, we examined the frequency and proportion of breast cancer patients according to thyroid status at baseline and during follow-up using euthyroidism as a reference group.

We used Cox regression models to compute crude and adjusted hazard ratios (HR) including 95% confidence intervals (95% CI) comparing the risk of recurrence and all-cause mortality, respectively, according to thyroid status (normal thyroid versus prevalent/incident hypothyroidism) \[[@CR32]\]. The proportional hazard assumption was checked by visual inspection of the log of the estimated survivor function in the models involving prevalent hypothyroidism (Additional file [2](#MOESM2){ref-type="media"}). The models accounted for competing risks and included adjustments for potential confounding covariates including age at diagnosis (continuous), menopausal status, UICC stage, ET/ER status, surgery type, receipt of chemotherapy, histologic grade, comorbidity, and use of simvastatin or aspirin, respectively. Simvastatin and aspirin use were modelled as time-varying covariates lagged by 1 year after redemption of a prescription and lasting for 1 year. Simvastatin and aspirin use were included in the adjusted models as they have been linked to breast cancer prognosis, and adherence to one medication may correlate with adherence to another prescription \[[@CR33], [@CR34]\]. Due to the low number of events in the incident model, we used a directed acyclic graph (DAG) to identify the relevant confounders for recurrence (please see Additional file [3](#MOESM3){ref-type="media"}). The final DAG adjusted model included age at diagnosis, UICC stage, chemotherapy, type of primary surgery, and ER/ET status.

In both models, we investigated potential effect measure modification stratifying by menopausal status, chemotherapy, and ET/ER use and for the incident model also stratifying by radiotherapy. In sensitivity analyses, we increased the lag time from 1 to 2 years. For recurrence, we also performed sensitivity analyses restricting to patients who had hypothyroidism 2, 5, and 10 years before their breast cancer diagnosis to investigate the association of duration of hypothyroidism with breast cancer recurrence.

All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).

Results {#Sec8}
=======

In the DBCG registry, 38,442 Danish women ≥ 35 years were diagnosed with non-metastatic breast cancer between 1996 and 2009. Due to reasons outlined in Fig. [1](#Fig1){ref-type="fig"}, 2979 (8%) women were excluded, and so the final study population included 35,463 women with early stage I-III, operable breast cancer.

At baseline, 34,191 (96%) women with breast cancer had a normal thyroid and 1272 (4%) had hypothyroidism with a follow-up time of 205,529 and 7112 person-years, respectively. Women with normal thyroid function were followed for a median of 6.0 years, and women with prevalent hypothyroidism for 5.6 years. Women with prevalent hypothyroidism were older, were more frequently post-menopausal, had more comorbidity, were less likely to be assigned chemotherapy, and were more often simvastatin users compared with their euthyroid counterparts (Table [1](#Tab1){ref-type="table"}).Table 1Baseline characteristics of women diagnosed with stage I--III, operable breast cancer in Denmark from 1996 to 2009, according to thyroid status at the time of breast cancer diagnosisCharacteristicsPrevalent hypothyroidismIncident hypothyroidismThyroid statusFollow-up time^1^Thyroid statusFollow-up time^1^Normal (*n* = 34,191)Hypothyroidism (*n* = 1272)NormalHypothyroidismNormal (*n* = 33,332)Hypothyroidism (*n* = 859)NormalHypothyroidismCalendar year of diagnosis, *n* (%) 1996--19998059 (24)199 (16)47,91711667888 (24)171 (20)47,339679 2000--200411,522 (34)413 (32)76,332256211,226 (34)296 (34)75,2041127 2005--200914,610 (43)660 (52)81,280338314,218 (43)392 (46)80,0041276Age at diagnosis, *n* (%) 35--40 years1172 (3)11 (1)7366621147 (3)25 (3)727789 40--49 years6134 (18)115 (9)40,0777085961 (18)176 (20)39,441637 50--59 years10,798 (32)346 (27)68,364208910,511 (32)287 (33)67,2811084 60--69 years11,020 (32)494 (39)64,885290110,759 (32)261 (30)63,951934 70--79 years4434 (13)263 (21)22,54012084333 (13)101 (12)22,226318 ≥ 80 years633 (2)43 (3)2296144621 (2)12 (1)227124Menopausal status at diagnosis, *n* (%) Premenopausal9378 (27)≤ 195^2^ (−)61,40411589118 (27)≤ 265^2^ (−)60,452952 Postmenopausal24,774 (72)1083 (85)143,944593724,176 (73)598 (70)141,8162128 Unknown39 (0)≤ 5^2^ (−)1811738 (0)≤ 5^2^ (−)1802Modified comorbidity status, *n* (%)^3^ None28,809 (84)957 (75)177,395551028,093 (84)716 (84)174,7812614 Low4587 (13)258 (20)24,59113564466 (13)121 (14)24,182409 High795 (2)57 (4)3542245773 (2)22 (3)348458Tumour size, *n* (%) ≤ 20 mm20,756 (61)≤ 775^2^ (−)128,360447920,248 (61)≤ 515^2^ (−)126,4631896 21--50 mm12,202 (36)480 (38)71,284249711,873 (36)329 (38)70,1861098 ≥ 51 mm1045 (3)23 (2)48781131026 (3)19 (2)479583 Unknown188 (1)≤ 5^2^ (−)100722185 (1)≤ 5^2^ (−)10034Lymph node status, *n* (%) N018,396 (54)724 (57)111,451404017,986 (54)410 (48)109,9881463 N1--310,391 (30)353 (28)66,956214510,090 (30)301 (35)65,8331123 N4+5404 (16)195 (15)27,1219275256 (16)148 (17)26,625496UICC stage, *n* (%) I13,433 (39)519 (41)81,013293913,139 (39)294 (34)79,9501063 II15,067 (44)551 (43)95,812320614,654 (44)413 (48)94,3031509 III5691 (17)202 (16)28,7049675539 (17)152 (18)28,194510Histological grade, *n* (%)^4^ Low9740 (28)364 (29)59,62720299500 (29)240 (28)58,749878 Moderate12,742 (37)507 (40)78,631291812,397 (37)345 (40)77,3511280 High6608 (19)226 (18)37,18611706446 (19)162 (19)36,641545 Unknown5101 (15)175 (14)30,0859954989 (15)112 (13)29,705379ER status, *n* (%) ER negative (0--9%)6376 (19)224 (18)35,44611116198 (19)178 (21)34,822624 ER positive (≥ 10%)26,954 (79)1031 (81)164,836589426,294 (79)660 (77)162,4482388 Unknown861 (3)17 (1)5247106840 (3)21 (3)517670HER-2 status, *n* (%)^5^ Negative11,551 (34)474 (37)63,723237011,245 (34)306 (36)62,732992 Positive2489 (7)114 (9)13,5085992426 (7)63 (7)13,317191 Unknown20,151 (59)684 (54)128,298414319,661 (59)490 (57)126,3981900Endocrine therapy and ER status, *n* (%) ET−/ER−7010 (21)231 (18)39,28311546819 (20)191 (22)38,615667 ET+/ER+17,592 (51)679 (53)113,800412317,109 (51)483 (56)112,0741725 ET−/ER+9362 (27)352 (28)51,03717719185 (28)177 (21)50,374663 ET+/ER−227 (1)10 (1)141064219 (1)8 (1)138426Type of primary surgery, *n* (%) Mastectomy without radiotherapy11,337 (33)454 (36)65,458237911,101 (33)236 (27)64,585873 Mastectomy with radiotherapy6897 (20)187 (15)41,41810456692 (20)205 (24)40,708710 Lumpectomy with radiotherapy15,957 (47)631 (50)98,653368815,539 (47)418 (49)97,1541499Systemic therapy, *n* (%) No2091 (6)73 (6)10,2652692046 (6)45 (5)10,089176 Yes32,100 (94)1199 (94)195,265684331,286 (94)814 (95)192,3582906Chemotherapy, *n* (%) No23,233 (68)965 (76)135,848527722,713 (68)520 (61)133,9331915 Yes10,958 (32)307 (24)69,681183510,619 (32)339 (39)68,5141167Endocrine therapy, *n* (%) No16,117 (47)577 (45)88,710288515,754 (47)363 (42)87,3961314 Yes18,074 (53)695 (55)116,819422717,578 (53)496 (58)115,0511768Radiotherapy, *n* (%) No11,337 (33)454 (36)65,458237911,101 (33)236 (27)64,585873 Yes22,854 (67)818 (64)140,071473322,231 (67)623 (73)137,8622209Co-medication at baseline, *n* (%) Simvastatin user1791 (5)135 (11)93217161753 (5)38 (4)9217103 Aspirin user447 (1)23 (2)2540117439 (1)8 (1)250336^1^In person-years. ^2^According to Danish Data Protection Law, cell with very few individuals are not allowed to be presented. ^3^Charlson Comorbidity Index (CCI) without cancer included (low: score of 1 or 2; high: score of 3 or more). ^4^Histological grade is based on a composite score including tubule formation, mitoses, and nuclear pleomorphy, all consistent of a score of 1, 2, or 3. The scores are summarised, and a total score of 3--5 is categorised as low grade, 6--7 as moderate grade, and 8--9 as high grade (<http://www.dbcg.dk/PDF%20Filer/Kap_3_Patologi_22_juni_2017.pdf>). ^5^Systematic recording of HER-2 status started in 2007 HER-2 is classified according to immunohistochemistry (Hercept test) and by fluorescent in situ hybridisation (FISH) (counts 60 dots, yet min 6 cells and max 60 cells). The ratio is given as gene/chromosome with 2 decimals. HER-2 positive includes 'HER-2 score = 3 and FISH ≤ 2.00'. HER-2 negative includes 'HER-2 score of 0, 1, or 2 and FISH ≤ 2.00'

During follow-up, 859 (2%) of the 34,191 women with normal thyroid at baseline developed hypothyroidism in a median follow-up time of 3.4 years. Compared with women with normal thyroid function, women who developed hypothyroidism during follow-up had a higher frequency of lymph node involvement and were more likely to be assigned chemo-, radio-, and/or endocrine therapy.

Recurrence {#Sec9}
----------

In total, 5626 (16%) women with normal thyroid function and 184 (14%) women with prevalent hypothyroidism developed recurrent breast cancer including 61% and 62% distant recurrences, respectively. Among women with incident hypothyroidism, 79 (9%) developed recurrence during follow-up of which 62% were distant recurrences.

After adjusting for potential confounding factors, women with prevalent hypothyroidism had a similar risk of recurrence as women with normal thyroid function (adjusted HR~prevalent~ 1.01, 95% CI 0.87--1.19). Likewise, there was little evidence of an association of incident hypothyroidism with breast cancer recurrence compared with normal thyroid function (adjusted HR~incident~ 0.93, 95% CI 0.75--1.16) (Table [2](#Tab2){ref-type="table"}).Table 2Breast cancer recurrence and all-cause mortality, HR, and associated 95% CIs for women diagnosed with stage I--III, operable breast cancer in Denmark from 1996 to 2009 by hypothyroidism present at breast cancer diagnosis (prevalent) or during follow-up (incident)RecurrenceAll-cause mortalityWomen with breast cancer (counts (%))Recurrent events (counts (%))Follow-up time (years)HR (95% CI)Women with breast cancer (counts (%))All-cause mortality (counts (%))Follow-up time (years)HR (95% CI)CrudeAdjustedCrudeAdjustedPrevalent hypothyroidism Normal thyroid34,191 (96)5626 (16)20,2881.001.0034,225 (96)9696 (96)36,9071.001.00 Prevalent hypothyroidism1272 (4)184 (14)5940.94 (0.81--1.09)1.01 (0.87--1.19)^1^1273 (4)398 (4)15551.25 (1.13--1.39)1.02 (0.92--1.14)^1^Incident hypothyroidism Normal thyroid33,332 (97)5547 (17)20,0751.001.0032,827 (96)9422 (97)36,5991.001.00 Incident hypothyroidism859 (3)79 (9)2131.00 (0.80--1.24)0.93 (0.75--1.16)^2^1398 (4)274 (3)3071.15 (1.02--1.30)1.08 (0.95--1.23)^1*HR*\ hazard\ ratio1^Adjusted for age at diagnosis, UICC stage, ER/ET use, surgery type, receipt of chemotherapy, menopausal status, comorbidity, histologic grade, and use of simvastatin or aspirin (as time-varying covariates updated daily and lagged by 1 year), respectively. ^2^Adjusted for age at diagnosis, UICC stage, ER/ET status, type of primary surgery, and chemotherapy

The findings were similar in pre-planned sensitivity analysis with drug exposures lagged by 2 years (data not shown). Stratifying by menopausal status, ER status, and receipt of chemotherapy and radiotherapy produced little change to the effect estimates as shown in Table [3](#Tab3){ref-type="table"}. Restricting the analysis to patients who had hypothyroidism 2, 5, and 10 years before breast cancer diagnosis did not alter the results substantially (adjusted HR~2year~ 1.00, 95% CI 0.84--1.18; adjusted HR~5year~ 0.88, 95% CI 0.71--1.10; adjusted HR~10year~ 0.91, 95% CI 0.63--1.31). The sensitivity analyses omitting surgery type and chemotherapy from the adjusted model did not alter the results (please see Additional file [2](#MOESM2){ref-type="media"}).Table 3Breast cancer recurrence and all-cause mortality, HR, and 95% CIs associating hypothyroidism status among stage I--III, operable breast cancer women diagnosed from 1996 to 2009 stratified by menopausal status, ER status, and chemo- and radiotherapyPrevalent hypothyroidismIncident hypothyroidism**RecurrenceRecurrence (counts)HR (95% CI)Recurrence (counts)HR (95% CI)**CrudeAdjusted^1^CrudeAdjusted^2^Menopausal status Premenopausal16531.00 (0.70--1.43)1.15 (0.79--1.69)16221.30 (0.91--1.87)1.24 (0.86--1.78) Postmenopausal41520.93 (0.79--1.09)0.99 (0.83--1.17)39990.87 (0.66--1.16)0.82 (0.61--1.08)ER status Positive42360.94 (0.79--1.11)1.00 (0.83--1.19)40990.97 (0.75--1.25)0.93 (0.71--1.20) Negative13911.04 (0.77--1.39)1.05 (0.76--1.45)13461.08 (0.68--1.73)1.02 (0.64--1.62)Chemotherapy^3^ Yes------19501.01 (0.72--1.50)0.97 (0.67--1.40) No------36760.98 (0.74--1.29)0.91 (0.69--1.21)Radiotherapy^3^ Yes------36430.96 (0.73--1.25)0.91 (0.69--1.20) No------19831.11 (0.75--1.63)0.99 (0.67--1.46)**All-cause mortalityMortality (counts)HR (95% CI)Mortality (counts)HR (95% CI)**CrudeAdjusted^1^CrudeAdjusted^1^Menopausal status Premenopausal17921.03 (0.73--1.47)1.19 (0.82--1.71)17601.24 (0.94--1.64)1.15 (0.85--1.55) Postmenopausal82981.17 (1.05--1.30)1.00 (0.89--1.12)79321.13 (0.99--1.29)1.06 (0.91--1.23)ER status Positive74181.25 (1.11--1.40)1.00 (0.88--1.13)71181.13 (0.99--1.30)1.06 (0.91--1.23) Negative23541.32 (1.07--1.63)1.20 (0.95--1.50)22631.27 (0.98--1.64)1.24 (0.93--1.64)Chemotherapy Yes24861.17 (0.92--1.48)1.15 (0.90--1.48)24161.18 (0.91--1.51)1.12 (0.85--1.47) No76081.23 (1.11--1.38)0.98 (0.87--1.11)72801.16 (1.00--1.33)1.06 (0.91--1.23)Radiotherapy^3^ Yes------53161.13 (0.96--1.33)1.08 (0.90--1.29) No------43801.22 (1.02--1.46)1.11 (0.91--1.34)*HR* hazard ratio^1^Adjusted for age at diagnosis, menopausal status, UICC stage, histologic grade, ER/ET use, surgery type, receipt of radio- and chemotherapy, comorbidity, and use of simvastatin or aspirin, respectively. ^2^Adjusted for age at diagnosis, UICC stage, ER/ET use, surgery type, and receipt of chemotherapy. ^3^Only evaluated for incident hypothyroidism

All-cause mortality {#Sec10}
-------------------

The study cohort for all-cause mortality included a further 35 women with breast cancer that had been excluded previously due to incomplete follow-up for recurrence. Overall, 10,094 women with breast cancer died during the study period of whom 398 (3%) were women with prevalent hypothyroidism and 274 (3%) were women who developed hypothyroidism during follow-up.

Women with prevalent hypothyroidism had a higher mortality risk than women with normal thyroid function (crude HR~prevalent~ 1.25, 95% CI 1.13--1.39), but the association attenuated after adjusting for confounders (adjusted HR~prevalent~ 1.02, 95% CI 0.92--1.14)---histological grade, UICC stage, type of surgery, and comorbidity burden.

Compared with women with normal thyroid function, women with incident hypothyroidism had a slightly increased risk of dying (crude HR~incident~ 1.15, 95% CI 1.02--1.30), which attenuated after adjusting for confounders (adjusted HR~incident~ 1.08, 95% CI 0.95--1.23)---histological grade, UICC stage, type of surgery, and comorbidity burden.

Stratifying by menopausal status, ER status, and receipt of chemotherapy and radiotherapy did not alter these findings (Table [3](#Tab3){ref-type="table"}). Furthermore, restricting to patients with prevalent hypothyroidism in 2, 5, and 10 years, or drug exposures lagged by 2 years did not affect the estimates substantially (data not shown).

Discussion {#Sec11}
==========

Evidence from our large cohort study does not support an association between hypothyroidism present at the time of diagnosis or during follow-up and breast cancer recurrence and all-cause mortality. For both recurrence and all-cause mortality, the near-null findings were not modified after stratification by menopausal status, ER status, chemotherapy, or radiotherapy or by duration of hypothyroidism prior to breast cancer diagnosis.

Our study has several strengths. We studied a large, nationwide cohort of women with breast cancer treated in a tax-supported and uniformly organised health care system with complete follow-up. Thus, selection bias seems unlikely. Furthermore, all breast cancer patients registered in the DBCG undergo standardised medical follow-up visits up to 10 years after primary diagnosis and any recurrent breast cancers are systematically registered in the DBCG \[[@CR24]\]. Overall, 77% of patients diagnosed with an incident breast cancer from 2006 to 2015 attended the entire follow-up programme with higher attendance among younger patients (\~ 81%) compared with patients aged over 75 years (\~ 74%). In addition, the systematic collection of data on clinical, tumour, and treatment characteristics on all breast cancer patients enabled us to account for important potential confounders that could affect the risk of recurrence and mortality. The completeness of the DNPR is high \[[@CR28]\]. The positive predictive value is 80, in general, and higher for conditions that always lead to hospitalisation. However, for conditions like hypothyroidism, the completeness may not be as high as this is often treated outside a hospital setting by a general practitioner. We therefore supplemented our study using data from the Danish National Prescription Registry. In the models of incident hypothyroidism, we used a time-varying approach to eliminate immortal time bias and lagged the exposure to eliminate reverse causation \[[@CR31], [@CR35]\].

Our study is also subject to some limitations. Hypothyroidism is underreported in the general population probably due to non-specific symptoms such as weight gain, fatigue, and memory loss, all of which may increase with age \[[@CR4], [@CR36]\]. In this study, we defined hypothyroidism from diagnosis codes or redeemed prescriptions but not by measures of hormone levels in blood samples as these were unavailable. Therefore, we cannot comment on the relationship between underlying hormone levels and breast cancer recurrence. In addition, we had no information on untreated subclinical hypothyroidism. We therefore cannot rule out the likelihood of undiagnosed and thus misclassified hypothyroidism among the women with breast cancer, which may bias our findings towards the null. Furthermore, our findings may be prone to residual confounding---for example, information on medication use (dosage and prescription compliance) and lifestyle factors associated with breast cancer or hypothyroidism (smoking, obesity, and physical activity) were not captured by the registries \[[@CR37], [@CR38]\]. Given the absence of data on actual hormone levels, an analysis comparing actual thyroid hormone values to recurrence risk could not be performed. Last, our definition of hypothyroidism was based on diagnostic codes and/or prescriptions for levothyroxine substitution therapy. As such, the impact of treating hypothyroidism may dilute the effect of hypothyroidism on recurrence. In total, 96.7% of the women with hypothyroidism in our study were on levothyroxine substitution. This may be a potential reason why our hypothesis of a positive effect of hypothyroidism on recurrence, as suggested by the laboratory models, was not confirmed \[[@CR20], [@CR21]\].

Previous studies on the association of thyroid function with survival in breast cancer patients have compared survival according to levels of thyroid hormones \[[@CR39], [@CR40]\] or using cancer-free controls \[[@CR37], [@CR41], [@CR42]\]. To our knowledge, only two studies have investigated the association of hypothyroid disease with survival in a cohort of breast cancer patients \[[@CR43], [@CR44]\]. However, one of these---the Malmø Diet and Cancer Study by Brandt et al.---is not comparable to ours as thyroid hormone measurements were collected at the time of inclusion into the study, on average 5 years before the time of breast cancer diagnosis \[[@CR44]\]. The study by Fiore et al. only included breast cancer patients with aggressive tumours and performed blood tests to assess thyroid function after surgery and before treatment \[[@CR43]\]. By measuring actual levels of thyroid hormone, they were able to detect not only overt hypothyroidism but also subclinical hypothyroidism. However, their study was small, including only 47 patients and only two cases of subclinical hypothyroidism; thus, estimates were presented for all types of thyroid dysfunction. Similarly, a study by Jiskra et al. was hampered by a small sample size (84 patients) and consequently had a low number of cases with hypothyroidism \[[@CR37]\]. Jiskra et al. also found no association of levels of thyroid hormones with relapse-free or overall survival in breast cancer patients compared with cancer-free controls. However, these latter two studies were likely underpowered for the hypothyroidism-breast cancer association. Thus, our prospective cohort study is the first to distinguish between the association of prevalent and incident hypothyroidism on the risk of breast cancer recurrence and overall mortality.

In our data, we note that 91% of patients with hypothyroidism were retrieved from the prescription registry, while the remainder were ascertained based on hospital diagnoses of hypothyroidism. This is not surprising as most cases of hypothyroidism are likely to be diagnosed and treated by a general practitioner. Furthermore, this highlights the importance of considering both diagnostic codes and prescription medications in future studies on hypothyroidism.

Conclusion {#Sec12}
==========

This prospective cohort study suggests that hypothyroidism present at the time of diagnosis or incident during follow-up is not associated with breast cancer recurrence or all-cause mortality. From a clinical point of view, this is reassuring for patients who suffer from hypothyroidism and for their physicians highlighting that hypothyroidism is unlikely to have an unfavourable impact on the clinical course of breast cancer or survival.
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